Study guide

10.3 Evaluating DLCO Validity

NBRC Registered Pulmonary Function Technologist RPFT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Content Outline Domains & Study Plan

2 Spirometry Instrumentation

2.1 Spirometer Types, Setup & Maintenance 2.2 Spirometer Calibration & Linearity 2.3 Spirometer Troubleshooting

3 Blood Gas & Gas Analyzers

3.1 Blood Gas Analyzer Setup, Maintain, Calibrate 3.2 Gas Analyzers & Water/Gas Absorbers 3.3 ABG & Gas Analyzer Troubleshooting and QC

4 Body Box, Exercise & Monitoring Equipment

4.1 Body Plethysmograph Setup & Calibration 4.2 Exercise, Field Walking & ECG Equipment 4.3 Pressure Devices, Valves & Gas Delivery Systems

5 Ancillary Equipment & Infection Control

5.1 Body Habitus, Sampling & Aerosol Equipment 5.2 Monitors & Emergency Management Equipment 5.3 Infection Control Materials & Methods

6 Quality Control Systems

6.1 Mechanical QC Devices 6.2 Biological Controls & Proficiency Testing 6.3 Laboratory Quality Management & SOPs

7 Patient Preparation & Safety

7.1 Body Habitus Measurements & Estimates 7.2 Patient Safety, Precautions & Adverse Events

8 Spirometry Procedures

8.1 Selecting Spirometry Protocols & Equipment 8.2 Performing Standard & Position-Variant Spirometry 8.3 Evaluating Spirometry Acceptability & Repeatability 8.4 Bronchodilator Response Studies

9 Static Lung Volumes

9.1 Gas Dilution Lung Volume Methods 9.2 Body Plethysmography Lung Volumes 9.3 Evaluating Lung Volume Validity

10 Diffusing Capacity (DLCO)

10.1 DLCO Protocol & Equipment Selection 10.2 Performing the DLCO Maneuver 10.3 Evaluating DLCO Validity

11 Blood Gas Sampling & Analysis Procedures

11.1 Arterial & Capillary Blood Sample Collection 11.2 Performing Blood Gas Analysis 11.3 CO-oximetry / Hemoximetry Procedures

12 Airway Responsiveness, Resistance & Muscle Strength

12.1 Bronchial Provocation Studies 12.2 Airways Resistance & Conductance by Plethysmography 12.3 Respiratory Muscle Strength (MIP/MEP/CPF)

13 Exercise, Oxygen, Home Testing & Education

13.1 Field Walking Tests (6MWT, Shuttle) 13.2 Monitored Exercise Testing 13.3 Oxygen Assessment & Titration 13.4 Home Testing Instruction & Patient Education

14 Calculations & Reference Ranges

14.1 Spirometry Calculations & Reference Equations 14.2 Lung Volume & DLCO Calculations/Corrections 14.3 Blood Gas & CO-oximetry Derived Calculations 14.4 Exercise, Oximetry & Special Test Calculations

15 Evaluating Result Reliability

15.1 Spirometry & Lung Volume Reliability 15.2 DLCO & Exercise Test Reliability 15.3 ABG, Monitoring & QC Reliability

16 Clinical Implications & Reporting

16.1 Pattern Recognition: Obstruction, Restriction, Mixed, Severity 16.2 Clinical Implications: DLCO, ABG, Airway Response, Exercise & Lab Context

10.3 Evaluating DLCO Validity

Key Takeaways Explain This Topic AI

Acceptable DLCO-SB trials require inspired volume near vital capacity (commonly VI ≥ 90% of the largest VC), breath-hold time in the standards window (~10 ± 2 s), and proper washout plus alveolar sample collection.

The 2017 ERS/ATS standard requires at least two acceptable maneuvers whose DLCO values agree within 2 mL/min/mmHg (0.67 mmol/min/kPa)—an absolute tolerance, with no percentage alternative—and the mean of those tests is reported.

Common technical failures include leak, Valsalva or Müller maneuvers, incomplete inspiration, poor sample timing, and inadequate inter-trial recovery.

Elevated COHb (e.g., recent smoking) primarily threatens interpretation and serial comparison even when the maneuver looks timed correctly—document and apply lab correction policy rather than ignoring it.

DCO II.C.9 requires evaluating validity of DLCO results before reporting values for clinical use.

Last updated: August 2026

Validity is a scored skill (II.C.9)

Domain II.C Evaluate task II.C.9 asks whether DLCO data are fit to report . A maneuver can look dramatic on the screen and still fail inspired-volume, timing, sample, or repeatability rules. High-cut RPFT items present pairs of trials, VI/VC ratios, breath-hold times, or clinical notes (smoking, strain) and expect you to accept, reject, repeat, or qualify the result.

Validity review assumes you already selected the protocol (10.1) and coached the sequence (10.2). Here you apply ATS/ERS single-breath DLCO standards concepts used throughout contemporary labs. Exact software flags vary by manufacturer; exam success comes from knowing what good looks like and which failures matter .

  • Acceptability criteria—major pillars
  • 1. Inspired volume relative to vital capacity (VI / VC)

The patient must inspire a volume of test gas that is a large fraction of vital capacity . ATS/ERS-aligned teaching emphasizes:

VI ≥ 90% of the largest measured VC (same visit) as a core acceptability target for adults.

VI much below VC under-fills the lung, misrepresents alveolar volume available for exchange, and often yields non-comparable DLCO.

  • VI vs largest VC Validity lean
  • ≥ 90% Meets common inspired-volume acceptability target
  • 85–89% Borderline—lab may allow with caution or require repeat; know SOP
  • ≪ 90% (e.g., 70%) Reject; reteach RV→TLC inspiration
  • VI > VC due to measurement mismatch Investigate VC quality, leak, or volume calibration—do not ignore

Worked example: Largest VC today = 4.00 L. Trial A VI = 3.70 L → 3.70/4.00 = 92.5% → inspired-volume OK. Trial B VI = 3.20 L → 80% → reject for incomplete inspiration even if breath-hold was exactly 10.0 s.

Exam trap: “Breath-hold was perfect, so low VI is fine.” Timing cannot rescue inadequate inspiration.

2. Breath-hold time (BHT)

Target ~10 seconds .

Acceptability is commonly framed as 10 ± 2 seconds (about 8–12 s ).

Too short → insufficient exchange time / unstable calculation assumptions.

Too long → patient strain, leak risk, and departure from standardized conditions.

  • BHT Typical action
  • 8–12 s Accept for timing if other criteria met
  • 6–7 s or >12–13 s Reject or repeat; reteach counting and TLC cue
  • Unstable (mid-hold leak flow) Reject even if clock says 10 s

Know how your system defines BHT (Jones–Meade and related timing methods exist in standards literature). For the exam, emphasize ~10 s target and reject clearly out-of-window holds .

3. Sample collection quality (washout + alveolar sample)

Valid calculation needs alveolar gas that is not dead-space contaminated and not mixed with a fresh inspiration :

Washout volume must be adequate to clear anatomic and apparatus dead space before sampling (adult default often ~0.75–1.0 L, reduced when VC is small per rules).

Alveolar sample volume must be sufficient for analyzers and drawn from the appropriate exhaled segment.

Sample during continuous expiration without inspiratory interruption.

Watch for analyzer lag , water in the sample cell, or exhausted absorbers producing impossible tracer/CO relationships.

  • Sample problem Likely effect
  • Washout too small Dead-space gas in “alveolar” sample → erroneous FCO/Ftracer
  • Sample too late / exhaled volume too small Unstable or non-alveolar gas; reject
  • Inspiration during sample Contamination; reject
  • Leak during hold or sample Room air dilutes CO and tracer → distorted DLCO and VA
  • 4. No major maneuver artifact

Even with VI and BHT in range, reject trials with:

  • Mouth or nose leak
  • Clear Valsalva or Müller physiology/coaching signs
  • Cough that interrupts hold or sample
  • Failure of valve switching (room air instead of test gas, or premature sample path)
  • Repeatability between acceptable maneuvers

Acceptability is per trial; repeatability is across trials. ATS/ERS DLCO standards concepts require more than one good maneuver:

Obtain at least two acceptable tests.

DLCO values must agree within 2 mL/min/mmHg (0.67 mmol/min/kPa) of each other. The 2017 ERS/ATS standard states this as a single absolute tolerance — it dropped the older 2005 “3 mL/min/mmHg or 10%” alternative. Do not fall back on a percentage escape hatch: two trials of 40.0 and 37.0 differ by 3.0, which is under 10% but fails the current criterion.

Report the mean of acceptable, repeatable maneuvers (not the single highest “hero” trial that fails pairing).

Numeric repeatability examples

  • Trial DLCO (mL/min/mmHg) Assessment
  • 22.0 and 21.5 Difference 0.5 → repeatable
  • 18.0 and 16.5 Difference 1.5 → repeatable on absolute criterion
  • 30.0 and 26.0 Difference 4.0 (>2) → not repeatable ; need another acceptable trial
  • 40.0 and 37.0 Difference 3.0 (>2) → not repeatable , even though it is under 10% of the higher value
  • 12.0 and 10.5 Difference 1.5 (≤2) → repeatable ; still verify both are acceptable on VI/BHT/sample

If two trials are each “pretty” but disagree widely, do not average junk —find a third acceptable trial or document limited reproducibility after max safe attempts.

VA and DLCO/VA checks (supporting validity sense)

Large swings in VA between trials often track inconsistent inspired volume, leak, or sample problems. Stable VI with unstable VA suggests technical artifact. Use these as clues while primary formal rules remain VI, BHT, sample, and DLCO repeatability.

Common failures—recognition table

Failure Clues during review Effect on numbers Technologist action

Leak (lips/nose/circuit) Volume loss in hold, patient feels air, tracer/CO pattern odd Often ↓ DLCO , wrong VA Reject; reseal; clip; filter; tubing

Valsalva Strain, red face, high mouth pressure if monitored Often ↓ DLCO Reject; reteach relaxed open-glottis hold

  • Müller Sucking effort against closed glottis Often ↑ DLCO Reject; reteach passive hold
  • Incomplete inspiration VI ≪ VC Non-comparable / low-quality DLCO Reject; coach RV empty + full TLC
  • Short/long BHT Clock outside ~8–12 s Nonstandard uptake time Reject; practice timing

Poor washout/sample Flags for dead space or small sample Erratic FCO/Ftracer Adjust sample settings if allowed; reteach smooth exhale

Back-to-back trials <4 min spacing Rising COHb, residual gas bias Enforce recovery; may discard later trials

Wrong test gas / tracer setup Impossible concentrations Entire set invalid Stop; fix configuration; repeat session setup

High COHb and interpretation—validity vs reporting caveat

Elevated carboxyhemoglobin (recent smoking, exposure, many prior DLCO trials) reduces measured DLCO. Important distinctions for II.C.9:

The maneuver may still meet VI, BHT, and sample rules—so it can be technically acceptable as a performance.

The result may still be misleading for disease comparison if COHb is high and uncorrected/unnoted.

RPFT behavior: document smoking/COHb , apply lab COHb adjustment when measured values and policy allow, and avoid declaring “new ILD progression” on a same-day post-cigarette study without technical commentary.

COHb is therefore both a pre-test selection issue (10.1) and a post-test validity/reporting qualifier (II.C.9) —stems may place it in either frame.

Other interpretation-linked factors (usually beyond pure “accept/reject curve” but often bundled in evaluate items):

  • Hb correction availability (anemia/polycythemia)
  • FiO₂ / supplemental O₂ state during test
  • Altitude and reference set consistency for serial tests
  • Session grading workflow (exam-ready)

After each trial, check VI/VC , BHT , leak/strain flags, and sample markers.

Label trial acceptable or reject with reason in the worksheet.

After ≥2 acceptable trials, test repeatability (within 2 mL/min/mmHg ).

If not repeatable, add trials only within recovery interval and max trial limits.

If limits reached without a repeatable pair, report best available with quality grade / comments , or “unable to obtain reproducible DLCO,” per medical-director policy— never silently publish a single outlier as definitive.

Attach Hb , smoking/COHb , and O₂ notes for the interpreter.

  • Quality outcome examples
  • Example A — Reportable
  • VC 3.50 L
  • Trial 1: VI 3.25 L (93%), BHT 10.2 s, DLCO 24.0, no leak
  • Trial 2: VI 3.30 L (94%), BHT 9.8 s, DLCO 23.4
  • Difference 0.6 → mean DLCO 23.7 reportable; Hb applied per policy
  • Example B — Incomplete inspiration
  • VC 3.50 L; VI 2.40 L (69%), BHT 10.0 s, DLCO 19.0
  • Reject despite perfect clock time; reteach
  • Example C — Non-repeatable
  • Two acceptable trials: DLCO 28 and 23 (diff 5)
  • Need additional acceptable trial or limited study comment— do not average 28 and 23 as if repeatable
  • Example D — Smoking caveat
  • Two repeatable trials, VI/BHT perfect, patient smoked 20 minutes prior, COHb high if measured

Technically repeatable set with interpretation caveat ; do not treat as clean baseline for drug-toxicity trending without note/correction pathway

Relationship to other tests in the visit

Compare VA from DLCO with TLC from dilution/box when available; large unexplained discordance prompts technical review of both methods (volume chapter links).

Severe obstruction may make SB inspiration and sample harder—validity may be limited even with excellent coaching; document.

Do not “fix” a failed DLCO by rewriting BHT in the database without a real maneuver.

RPFT validity vignettes

Vignette 1: Software green-checks two trials with VI 78% and 80% of VC because BHT was 10 s. Action: override false confidence— reject on inspired volume; standards care about VI/VC, not only the timer.

Vignette 2: DLCO 25 then 18; both VI >90%, BHT OK; patient strained on second hold. Action: reject second as Valsalva-suspect; repeat after coaching; do not average 25 and 18.

Vignette 3: Only one acceptable trial after five attempts. Action: report single trial only with explicit quality limitation if policy allows, or unable—do not invent a second value.

Link to practice and later chapters

II.C.9 is the gate before Domain III-style interpretation of low/high DLCO patterns, Hb/COHb math detail, and clinical implications. Drill procedure and validity stems with free RPFT practice at /practice/rpft . Equipment QC for CO/tracer analyzers remains Domain I; calculations and clinical patterns continue in later study-guide chapters on volume/DLCO math and gas-exchange implications.